Sharemaestro Newsreel

Viatris Inc. stock rises Friday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.18% to $16.23 on Friday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain ended a two-day losing streak for Viatris, indicating a resilient performance against broader …

Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics?

Steris PLC stock outperforms competitors despite losses on the day

Steris PLC stock (STE) fell 1.18% to $233.28 on Friday, marking its fourth consecutive day of losses. Despite this, the stock outperformed the broader market, as the S&P 500 Index (SPX) dropped 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%.

Labcorp Holdings Inc. stock outperforms competitors despite losses on the day

Shares of Labcorp Holdings Inc. (LH) experienced a 1.38% drop on Friday, closing at $318.13. Despite this loss and an overall poor trading day for the stock market, with the S&P 500 and Dow Jones also falling, Labcorp's stock still outperformed its competitors. This …

DYAI: Second Quarter Results

DexCom Inc. stock underperforms Friday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.89% to $89.75 on Friday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. This drop ended a six-day winning streak for the company's stock.

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

IM Cannabis reports Q2 results

IM Cannabis press release [https://seekingalpha.com/filing/309949813] (IMCC [https://seekingalpha.com/symbol/IMCC]): Q2 revenue of $7.6 million, compared to $12.7 million in the same period in 2025. * Gross profit of $1.5 million, compared to $3.4 million in the same period in 2025. * Operating loss of $2.1 million, …

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO …

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake

Squadron Master Fund LP and its related parties, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have disclosed a 1.6% equity stake in NextCure, Inc. through a SCHEDULE 13G/A SEC filing. This group beneficially owns 64,464 shares of NextCure common stock and …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Satellos Bioscience Inc. GAAP EPS of -$0.56

* Satellos Bioscience Inc. press release [https://seekingalpha.com/filing/309950026] (MSCL:CA [https://seekingalpha.com/symbol/MSCL:CA]): Q2 GAAP EPS of -$0.56. * Research and development expenses increased by $5,200 to $9,635 for the three months ended June 30, 2026, compared to $4,435 for the three months ended June 30, 2025, and …

Cigna Group stock outperforms competitors on strong trading day

Cigna Group (CI) shares rose 1.64% to $282.56, outperforming the broader market on a day when the S&P 500 and Dow Jones Industrial Average both fell. This marks the third consecutive day of gains for Cigna Group's stock.

LifeStance Health Group (LFST) Turned Profitable And Lifted Guidance, Is It Still Below Fair Value?

Cooper Creek’s 9.6% WW International (WW) stake detailed in Schedule 13G/A

Cooper Creek Partners Management LLC has reported a passive beneficial ownership of 9.6% in WW International, Inc. (WW), amounting to 961,719 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares and certifies that the stake is …

HTFL Stock Rockets On Heavy Volume As Traders Pile In

Heartflow, Inc. (HTFL) stock surged over 30% due to optimism surrounding its AI-driven cardiovascular imaging breakthrough. The company, despite running deep losses, boasts strong gross margins, a robust cash position, and low debt, making it attractive for momentum traders despite its speculative growth profile. …

Dianthus Therapeutics stock hits 52-week high at 114.64 USD

Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a …

Palatin Technologies (PTN) gains 4.7% stake holder AuGC BioFund in 13G/A

AuGC BioFund LP, along with AuGC Partners LLC and Evan Markegard, has reported a beneficial ownership of 84,000 shares of Palatin Technologies Inc. common stock, representing 4.7% of the total outstanding class. This ownership confers shared voting and dispositive power over the shares. The …

Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses

Alphatec Holdings (ATEC) saw its stock rise by 5.9% after announcing Q2 results that showed a narrowed net loss and reaffirmed its 2026 revenue guidance of approximately US$882 million. The company also filed an US$8.12 million shelf registration related to an ESOP offering. This …

TELA BIO (TELA): SilverArc Capital and Devesh Gandhi disclose 2.14M-share 4.8% stake

SilverArc Capital Management, LLC and Devesh Gandhi have filed an amended Schedule 13G, disclosing a beneficial ownership of 2,137,201 shares of TELA Bio, Inc. Class A Common Stock, representing 4.8% of the class. The filing indicates they hold shared voting and dispositive power over …

Deadline Alert: Insulet Corporation (PODD) Shareholders Who

Glancy Prongay Wolke & Rotter LLP is urging Insulet Corporation (NASDAQ: PODD) shareholders who lost money to contact them regarding a securities fraud lawsuit. The class action alleges Insulet made misleading statements and failed to disclose defective manufacturing controls, leading to product recalls and …

Innovative Eyewear (LUCY) grows revenue 74% but stays unprofitable in Q2 2026

Innovative Eyewear, Inc. (LUCY) reported a 74% increase in revenue for Q2 2026, reaching $1,010,519, primarily driven by strong sales of Lucyd Armor smart safety glasses and Reebok-branded smartglasses. Despite the significant revenue growth and improved gross margin of 24%, the company continued to …

Innovative Eyewear Reports 74% Revenue Growth in Q2

Innovative Eyewear reported a significant 74% year-over-year revenue growth in Q2 2026, reaching over $1 million for the first time. The company also improved its gross margin to 24% and reduced operating expenses, demonstrating effective cost management. With strategic initiatives and partnerships, Innovative Eyewear …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Is iRhythm Holdings (IRTC) Undervalued Following Earnings And Higher 2026 Guidance?

Stronger Results, Bigger Buyback and More Credit Capacity Might Change The Case For Investing In Cardinal Health (CAH)

What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders

Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake

Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have reported a beneficial ownership stake of 810,000 shares in Lipocine Inc. (LPCN). This represents 9.8% of the company's outstanding shares as of May 6, 2026. The …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics

The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says